BDRX · Biodexa Pharmaceuticals Plc
$1.71
-0.06 (-3.39%)
At close · Jul 22
Market Cap
$1.55M
Shares
904,066
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.71
Open$1.71
Day$1.65–1.83
52W$1.65–59.40
Avg vol 30d278K
Short int67K · 7.4% float · 1.0d
Short vol40%
Last earningsJun 30, 2021
DataJan 2020–Jul 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 16.6 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−86%
below
Price vs 50-day avg
−42%
below
RSI (14)
20
oversold
MACD trend
Negative
52-week position
0%
near low
Momentum
relative strength
1-month return
−36%
trailing
6-month return
−84%
trailing
YTD return
−85%
this year
Relative strength
−91%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $12 — 200d above 50d
Institutional flow
Distributing
2 of 8 funds reported for Jun 30 · net -2.3K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.45% of float · ▲ +759.2% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
8 holders — 13F breadth
Squeeze score
61
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
174%
annualized · 1-yr
Max drawdown
−97%
past year
ATR
14.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−86%
Bearish
Price vs 50-day avg
−42%
Bearish
RSI (14)
20
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $12 — 200d above 50d
Institutional flow
Distributing
2 of 8 funds reported for Jun 30 · net -2.3K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.45% of float · ▲ +759.2% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
8 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $2
Now $2 · 0%
52-wk high $59
vs 200-day avg -86%
vs 50-day avg -42%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BDRX
this stock
Biodexa Pharmaceuticals Plc
|
$1.55M | -84.9% | — | — | 7.4% |
|
ONC
BeOne Medicines Ltd.
|
$462.38B | +5.3% | +22179.2% | 941.0 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$119.94B | +4.2% | +46.2% | 28.1 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.27B | -15.5% | +20.8% | 15.9 | 3.3% |
|
ARGX
Argenx SE
|
$53.28B | +1.3% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
8
- % held
- 7.9%
- Reported
- 2 of 8
- Top holder
- SABBY MANAGEMENT, LLC
Held
Float
Short & Settlement
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BDRX | -23.7% | -35.7% | -83.6% | -41.2% | -84.9% |
| SPY | -1.0% | +1.9% | +7.5% | +0.1% | +9.6% |
| vs SPY | -22.7% | -37.6% | -91.0% | -41.3% | -94.5% |